These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27352067)

  • 1. Does ponatinib cross the blood-brain barrier?
    Abid MB; De Mel S
    Br J Haematol; 2017 Nov; 179(3):497-498. PubMed ID: 27352067
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
    Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
    J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
    Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, metabolism, and excretion of [
    Ye YE; Woodward CN; Narasimhan NI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
    Nickel RS; Daves M; Keller F
    Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
    [No Abstract]   [Full Text] [Related]  

  • 8. T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.
    Wang D; Pan H; Wang Y
    Leuk Lymphoma; 2017 Jul; 58(7):1733-1735. PubMed ID: 27813432
    [No Abstract]   [Full Text] [Related]  

  • 9. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Menna P; De Grazia U; Marchesi F; Minotti G; Salvatorelli E
    Chemotherapy; 2020; 65(1-2):35-41. PubMed ID: 32829325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia.
    Walczak P; Fodil S; Vignal N; Cabannes-Hamy A; Boissel N; Raffoux E; Cayuela JM; Goldwirt L; Lengliné E
    Blood; 2024 Sep; 144(10):1127-1130. PubMed ID: 38917352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Success is built on failures: tackling the challenge of ponatinib failure.
    Hiwase D; Ross D
    Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
    Thomas X
    Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
    [No Abstract]   [Full Text] [Related]  

  • 13. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
    Shah NP
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemia cutis with lymphoglandular bodies: a clue to acute lymphoblastic leukemia cutis.
    Obiozor C; Ganguly S; Fraga GR
    Dermatol Online J; 2015 Aug; 21(8):. PubMed ID: 26437164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
    [No Abstract]   [Full Text] [Related]  

  • 18. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
    Andrews C; Lipton J
    Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
    [No Abstract]   [Full Text] [Related]  

  • 20. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.